Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators.

ENCANTO is a randomized, controlled, multi-center phase II clinical trial for the treatment of patellofemoral osteoarthritis (PFOA) with an Advanced Therapy Medicinal Product (ATMP), nasal chondrocyte-based tissue engineered cartilage (N-TEC) implantation in comparison with current standard of care depending on the stage of osteoarthritis. The goal of this phase II trial is to evaluate the efficacy of N-TEC treatment in comparison to an active comparator Autologous Matrix Induced Chondrogenesis (AMIC) for early stage PFOA or patellofemoral arthroplasty (PFA) for late stage PFOA. The N-TEC engineered cartilage graft is obtained by culturing expanded autologous nasal chondrocytes within a collagen type I/III membrane.

NCT Number	NCT06576583
Lead Sponsor	University Hospital, Basel, Switzerland Collaborators: Clinical Trial Unit, University Hospital Basel, Switzerland, Wuerzburg University Hospital, Medical University of Vienna, Videoreha, University of Oulu, Theracell Laboratories, Promove-Biotec GmbH, Maastricht University, Foundation National Reumafonds, Angry@Arthritis, University of Miami, Geistlich Pharma AG, European Union
Conditions	Patellofemoral Osteoarthritis
Enrollment	150 participants
Start Date	2025-07-15
Primary Completion	2029-01 (estimated)
Study Completion	2030-01 (estimated)
Updated on ClinicalTrials.gov	2026-03-24